Cargando…
Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
This clinical trial (ChiCTR1800019185) is designed to be an open‐label, prospective, single‐center, single arm exploratory research study. The study will recruit non‐small cell lung cancer patients (NSCLC) with slow progression after first‐line treatment with EGFR‐TKI drugs. Slow progression will be...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049491/ https://www.ncbi.nlm.nih.gov/pubmed/31918452 http://dx.doi.org/10.1111/1759-7714.13303 |
_version_ | 1783502452056653824 |
---|---|
author | Li, Xin Liu, Minghui Zhang, Hongbing Liu, Hongyu Chen, Jun |
author_facet | Li, Xin Liu, Minghui Zhang, Hongbing Liu, Hongyu Chen, Jun |
author_sort | Li, Xin |
collection | PubMed |
description | This clinical trial (ChiCTR1800019185) is designed to be an open‐label, prospective, single‐center, single arm exploratory research study. The study will recruit non‐small cell lung cancer patients (NSCLC) with slow progression after first‐line treatment with EGFR‐TKI drugs. Slow progression will be confirmed by the presence of serum carcinoembryonic antigen or imaging evaluation. The primary aim is to assess progression‐free survival after EGFR‐TKIs treatment combined with apatinib 250 mg once daily. The secondary objectives are to evaluate objective efficacy, disease control rates, quality of life, overall survival, and safety. From September 2018 to September 2020, under specific entry and discharge standards, we plan to enroll 38 eligible patients until the end of the study. We hope that our study will help to explore a new way of combining the small molecular inhibitors of antiangiogenesis with EGFR‐TKIs to overcome acquired drug resistance. |
format | Online Article Text |
id | pubmed-7049491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-70494912020-03-05 Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185) Li, Xin Liu, Minghui Zhang, Hongbing Liu, Hongyu Chen, Jun Thorac Cancer Study Protocol This clinical trial (ChiCTR1800019185) is designed to be an open‐label, prospective, single‐center, single arm exploratory research study. The study will recruit non‐small cell lung cancer patients (NSCLC) with slow progression after first‐line treatment with EGFR‐TKI drugs. Slow progression will be confirmed by the presence of serum carcinoembryonic antigen or imaging evaluation. The primary aim is to assess progression‐free survival after EGFR‐TKIs treatment combined with apatinib 250 mg once daily. The secondary objectives are to evaluate objective efficacy, disease control rates, quality of life, overall survival, and safety. From September 2018 to September 2020, under specific entry and discharge standards, we plan to enroll 38 eligible patients until the end of the study. We hope that our study will help to explore a new way of combining the small molecular inhibitors of antiangiogenesis with EGFR‐TKIs to overcome acquired drug resistance. John Wiley & Sons Australia, Ltd 2020-01-09 2020-03 /pmc/articles/PMC7049491/ /pubmed/31918452 http://dx.doi.org/10.1111/1759-7714.13303 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Study Protocol Li, Xin Liu, Minghui Zhang, Hongbing Liu, Hongyu Chen, Jun Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185) |
title | Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185) |
title_full | Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185) |
title_fullStr | Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185) |
title_full_unstemmed | Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185) |
title_short | Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185) |
title_sort | clinical study of apatinib combined with egfr‐tki in the treatment of chronic progression after egfr‐tki treatment in non‐small cell lung cancer (chictr1800019185) |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049491/ https://www.ncbi.nlm.nih.gov/pubmed/31918452 http://dx.doi.org/10.1111/1759-7714.13303 |
work_keys_str_mv | AT lixin clinicalstudyofapatinibcombinedwithegfrtkiinthetreatmentofchronicprogressionafteregfrtkitreatmentinnonsmallcelllungcancerchictr1800019185 AT liuminghui clinicalstudyofapatinibcombinedwithegfrtkiinthetreatmentofchronicprogressionafteregfrtkitreatmentinnonsmallcelllungcancerchictr1800019185 AT zhanghongbing clinicalstudyofapatinibcombinedwithegfrtkiinthetreatmentofchronicprogressionafteregfrtkitreatmentinnonsmallcelllungcancerchictr1800019185 AT liuhongyu clinicalstudyofapatinibcombinedwithegfrtkiinthetreatmentofchronicprogressionafteregfrtkitreatmentinnonsmallcelllungcancerchictr1800019185 AT chenjun clinicalstudyofapatinibcombinedwithegfrtkiinthetreatmentofchronicprogressionafteregfrtkitreatmentinnonsmallcelllungcancerchictr1800019185 |